Brexit May Affect Drug Approvals in the UK


Regardless of how the UK decides to move forward, it could take several years before the implications of the vote to leave the EU are fully realized.

The European Medicines Agency (EMA) is currently responsible for reviewing and approving new drugs in the European Union (EU), including the United Kingdom (UK). New drugs can be further reviewed and appropriately priced by each country’s national regulatory body. For the UK, that body is the Medicines & Healthcare Products Regulatory Agency (MHRA).

Pharmaceutical companies wanting to sell new drugs or devices in the UK have to get them licensed by the MHRA, but an alternative route is to obtain centralized authorization from the EMA. The EMA is run by regulators from member states who staff its committees, amassing input from across the EU (including the UK for now) on each drug approval. This removes the need for a separate national process because once the EMA grants centralized authorization, it’s valid in both member states and countries in the European Economic Area (EEA), which includes all EU member countries as well as Iceland, Liechtenstein, and Norway.

Since the UK just voted to leave the EU, the EMA (which is currently located in London) will most likely be moved to a member country. Several have signaled interest, including Sweden, Denmark, and Italy. However, the move isn’t expected to occur any time soon, as it will require more than 600 regulatory and scientific experts to relocate.

If the UK decides to negotiate to stay in the EEA, there likely won’t be much difference in regulations because it’s possible that the MHRA could function like other regulatory agencies located in non-EU EEA countries, which work with the EMA even though they’re outside the EU. But, if the UK stays out of the EEA, drug companies would need to go through a separate process with British regulators for new products, as the EMA route wouldn’t be applicable to the UK.

On the other hand, the UK might follow the footsteps of Switzerland, a non-EU country that isn’t included in the EEA. Switzerland’s regulatory agency, Swissmedic, independently authorizes medical products but works with the EMA under mutual recognition and sharing agreements.

Regardless of how the UK decides to move forward, it could take several years before the implications of the vote to leave the EU are fully realized.

Related Videos
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U -
Image credit: Andrea Izzotti
Inflation Reduction Act is shown using the text and the US flag - Image credit: Andrii |
Pharmacy Interior | Image Credit: Tyler Olson -
Male pharmacist selling medications at drugstore to a senior woman customer | Image Credit: Zamrznuti tonovi -
Pharmacist assists senior woman in buying medicine in pharmacy - Image credit: Drazen |
Pharmacy, medicine and senior woman consulting pharmacist on prescription. Healthcare, shopping and elderly female in consultation with medical worker for medication box, pills or product in store - Image credit: C Daniels/ |
Image credit: fidaolga -
Pharmacists checking inventory at hospital pharmacy- Image credit: Jacob Lund |
Young male pharmacist giving prescription medications to senior female customer in a pharmacy | Image Credit: Zamrznuti tonovi -
© 2023 MJH Life Sciences

All rights reserved.